Bank of Montreal Can Sells 29,255 Shares of IQVIA Holdings Inc. $IQV

Bank of Montreal Can trimmed its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 16.7% in the second quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 146,317 shares of the medical research company’s stock after selling 29,255 shares during the quarter. Bank of Montreal Can owned 0.09% of IQVIA worth $23,058,000 as of its most recent filing with the SEC.

Other institutional investors have also recently bought and sold shares of the company. Verdence Capital Advisors LLC acquired a new position in IQVIA during the second quarter valued at approximately $3,612,000. Patton Fund Management Inc. bought a new stake in shares of IQVIA during the 2nd quarter worth approximately $231,000. Heritage Investors Management Corp boosted its holdings in shares of IQVIA by 10.5% in the 2nd quarter. Heritage Investors Management Corp now owns 104,704 shares of the medical research company’s stock valued at $16,500,000 after buying an additional 9,909 shares during the last quarter. Nordea Investment Management AB grew its stake in shares of IQVIA by 41.7% in the second quarter. Nordea Investment Management AB now owns 2,060,460 shares of the medical research company’s stock valued at $326,274,000 after buying an additional 606,391 shares in the last quarter. Finally, Private Advisor Group LLC raised its position in IQVIA by 11.6% during the first quarter. Private Advisor Group LLC now owns 5,435 shares of the medical research company’s stock worth $958,000 after acquiring an additional 566 shares in the last quarter. Institutional investors own 89.62% of the company’s stock.

Insider Buying and Selling at IQVIA

In other news, insider Eric Sherbet sold 4,000 shares of IQVIA stock in a transaction on Wednesday, October 29th. The stock was sold at an average price of $219.70, for a total transaction of $878,800.00. Following the completion of the sale, the insider owned 27,108 shares of the company’s stock, valued at approximately $5,955,627.60. This trade represents a 12.86% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 1.60% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have recently commented on IQV. William Blair reissued an “outperform” rating on shares of IQVIA in a research report on Wednesday, July 23rd. Jefferies Financial Group upgraded IQVIA from a “hold” rating to a “buy” rating and lifted their price target for the stock from $195.00 to $225.00 in a report on Tuesday, September 9th. Baird R W raised IQVIA from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, October 29th. Citigroup raised their price objective on IQVIA from $200.00 to $230.00 and gave the company a “neutral” rating in a research report on Wednesday, October 29th. Finally, Weiss Ratings reiterated a “hold (c)” rating on shares of IQVIA in a research note on Wednesday, October 8th. Two analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and six have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $239.94.

IQVIA Trading Down 0.2%

Shares of IQV stock opened at $210.50 on Friday. IQVIA Holdings Inc. has a 12-month low of $134.65 and a 12-month high of $225.00. The company has a market capitalization of $35.85 billion, a PE ratio of 28.88, a price-to-earnings-growth ratio of 2.36 and a beta of 1.34. The firm has a 50 day moving average price of $199.38 and a two-hundred day moving average price of $176.07. The company has a quick ratio of 0.70, a current ratio of 0.70 and a debt-to-equity ratio of 2.03.

IQVIA (NYSE:IQV) last announced its earnings results on Tuesday, October 28th. The medical research company reported $3.00 earnings per share for the quarter, topping analysts’ consensus estimates of $2.98 by $0.02. The company had revenue of $4.10 billion for the quarter, compared to analyst estimates of $4.07 billion. IQVIA had a return on equity of 30.70% and a net margin of 8.07%.The firm’s quarterly revenue was up 5.2% compared to the same quarter last year. During the same quarter last year, the company earned $2.84 earnings per share. IQVIA has set its FY 2025 guidance at 11.850-11.950 EPS. As a group, analysts predict that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.